Skip to content
Open access

Parallel neuroinflammatory pathways to cerebrovascular burden and amyloid beta in Alzheimer's disease

Jul 2026 · Alzheimer's & Dementia · Vol 18 · 1 citation · 47 references
Medicine

TL;DR

Higher plasma YKL‐40 was associated with greater white matter hyperintensity (WMH), whereas higher plasma GFAP was related to increased 18F‐florbetapir (FBP) standardized uptake value ratio (SUVR) and higher plasma p‐tau217 was associated with reduced MTL cortical thickness and hippocampal volume.

Abstract

Abstract INTRODUCTION Upstream neuroinflammation plays an important role in Alzheimer's disease (AD) but remains poorly understood. We tested whether two distinct neuroinflammatory markers are associated with cerebrovascular burden and amyloid beta (Aβ), and downstream, with plasma phosphorylated tau (p‐tau217), medial temporal lobe (MTL) cortical and hippocampal atrophy, and memory deficits.

Methods

Cognitively unimpaired older adults without dementia or mild cognitive impairment were recruited from a community sample (Biomarker Exploration in Aging, Cognition, and Neurodegeneration; [BEACoN]; N = 126). We used structural equation modeling to test whether plasma chitinase‐3‐like protein 1 (YKL‐40) and glial fibrillary acidic protein (GFAP) contribute to distinct pathways.

Results

Higher plasma YKL‐40 was associated with greater white matter hyperintensity (WMH), whereas higher plasma GFAP was related to increased 18F‐florbetapir (FBP) standardized uptake value ratio (SUVR). Higher plasma GFAP, WMH, and FBP SUVR were independently associated with increased p‐tau217. Plasma p‐tau217 was associated with reduced MTL cortical thickness and hippocampal volume. Reduced hippocampal volume was related to worse memory.

Discussion

Future work can further investigate these neuroinflammatory pathways as potential therapeutic targets for AD.

Read PDF

Similar papers

Aug 2026

Association Between Plasma GFAP and Medial Temporal Atrophy and Cognition in Amyloid-Negative Cerebrovascular Disease.

In Aβ-negative cognitively impaired individuals with high cerebrovascular burden, elevated plasma GFAP is associated with medial temporal atrophy and cognitive decline, suggesting GFAP may capture astrocyte-reactivity relevant to vascular cognitive impairment beyond amyloid pathology.

M. S. Oliveira-Junior, M. Rodrigues, Livia Amaral et al. · 0 citations
Open access Jul 2026

Relative importance of blood-based biomarkers for Alzheimer’s disease-specific neurodegeneration and cognitive decline

A stratified approach based on amyloid status is essential for the optimal application of blood-based biomarkers in monitoring disease progression and evaluating therapeutic efficacy in future clinical trials and precision medicine.

Keun You Kim, Hyunsun Ham, E. Yoon et al. · 0 citations
Review Open access Aug 2026

Mechanisms, Biomarkers and Therapeutic Implications of Neuroinflammation in Alzheimer's Disease

The dual and stage‐dependent roles of microglia and astrocytes are explored, discussion of blood–brain barrier dysfunction and peripheral immune infiltration as underappreciated pathogenic contributors are expanded, and emerging evidence linking neuroinflammation specifically to tau pathology is integrated.

S. Papelian · 0 citations
Open access Jul 2026

Relation of fluid neurodegeneration biomarkers with white matter integrity in Alzheimer's disease patients in Latin America

Serum NfL was associated with anatomically specific WM microstructural changes, with differing patterns across clinical groups, and no significant associations were observed between serum or CSF GFAP concentrations and diffusion tensor imaging metrics.

T. Magalhães, R. Casseb, A. Moraes et al. · 0 citations
Open access Jul 2026

Blood Biomarkers of Alzheimer's Disease and Patterns of Structural Brain Changes in the Community.

In cognitively unimpaired older adults, elevated blood p-tau217 was linked to faster shrinkage in AD-specific brain regions, whereas NfL and GFAP were associated with more widespread atrophy, with NfL also associated with accelerated WMH accumulation.

Martina Valletta, D. L. Vetrano, E. Laukka et al. · 0 citations
Open access Aug 2026

Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer’s disease

In this large longitudinal sample of asymptomatic individuals, the Aβ-dominant biomarker component showed the strongest association with longitudinal GM atrophy and cognitive decline, beyond the effects of tau pathophysiology and neuroaxonal injury.

W. Pelkmans, R. Cacciaglia, Michalis Kassinopoulos et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.